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“Non scholæ sed vitæ discimus” 
 
 
 
(We do not learn for school, but for life)  
 
In fond memory of my Grandmother, Anna-Brita Hellgren, who from an early 
age instilled in me this Latin phrase, as she helped me with my homework. 
My grandmother came from a family where education was seen as important, 
but the joy of learning was imperative. This joy of learning trickled down from 
my great-grandmother Lisa, a Baccalaureate, to my grandmother who passed 
it on to my mother, and then onto me.  
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ABSTRACT 
INTRODUCTION 
A condition can be suitable for population screening if the disease is an 
important health problem, can be detected by an appropriate test and has a 
silent/latent stage during which treatment could be initiated in order to 
prevent consequences of the disease. Atrial fibrillation (AF) increases the 
risk of ischemic stroke 5-fold, a risk that can be reduced by at least 64% by 
the use of stroke-preventive, oral anticoagulant (OAC) therapy, and there 
are several non-invasive methods that can be used to diagnose AF. Hence it 
could be argued that AF is suitable for population screening. 
The aim of this thesis is to study the feasibility of systematic screening for 
AF in a high risk population and the possibility to initiate stroke-preventive 
anticoagulant therapy. In addition, this thesis also aims to compare 
different biomarkers and their association with AF, and to study if the 
biomarker NT-proBNP is increased in screening-detected AF.  
Finally, different methods for the detection of AF in a population that has 
already suffered an ischemic stroke or transient ischemic attack will be 
explored.  
METHODS AND RESULTS 
In study I all residents born in 1936/37, n=28,768, and who resided in two 
Swedish regions, were randomized 1:1 either to a control group or to attend 
a screening study. Of the 13,331 individuals who were invited, 7,173 (54%) 
participated. New AF was detected in 218 participants (3.0 %, 95% 
confidence interval (CI) 2.7-3.5) using twice daily intermittent ECG 
recordings for 14 days. In addition, 149 participants were known to have 
AF, but were not treated with oral anticoagulant therapy. Of the screened 
population, 5.1% (95 % CI 4.6-5.7) had untreated AF. Initiation of OAC 
treatment was made in 93% of participants with newly detected AF and in 
3.7% (95% CI 3.3-4.2) of the screened population. 
Study II collected five different biomarkers: i) N-terminal pro-B-type 
Natriuretic Peptide (NT-proBNP) indicative of atrial stretch, ii) high-sensitive 
(hs) Troponin (Tn) as a marker of myocyte damage, iii) Growth differentiation 
factor -15 (GDF-15), which is a marker of oxidative stress, iv) the renal 
biomarker cystatin C and v) the inflammatory marker hs C-reactive protein 
(CRP), in two Swedish cohorts, the Uppsala Longitudinal Study of Adult 
Men (ULSAM), n=883 and the Prospective Investigation of the Vasculature 
in Uppsala Seniors (PIVUS), n=978. Risk factors for cardiovascular disease 
were assessed at the baseline visit. After a median follow-up of 12.6 years in 
ULSAM and 10 years in PIVUS, 113 (12.8%) patients developed AF in 
ULSAM and 148 (15.1%) in PIVUS. Unadjusted Cox regression analysis 
showed significant association for all biomarkers with regards to the 
development of AF; however, in analysis adjusted for cardiovascular risk 
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factors and the other biomarkers, only NT-proBNP remained significantly, p 
< 0.001, associated with incident AF with a hazard ratio of 2.05 (1.62-2.59) 
in ULSAM and 1.56 (1.30-1.86) in PIVUS per 1 standard deviation increase. 
NT-proBNP significantly increased risk prediction, both with regards to risk 
factors for cardiovascular disease and the established CHARGE-AF risk 
score. 
In study III the last 815 consecutive participants from study I had a sample 
of NT-proBNP analysed bedside, and 71 individuals with newly detected AF 
had NT-proBNP taken at cardiology follow-up. Participants with newly 
detected AF, n=96, had significantly higher NT-proBNP (median 330 ng/L, 
interquartile range (IQR)121;634), compared to individuals in whom AF was 
not detected, n=742, median NT-proBNP 171 ng/L (IQR 95;283), p < 0.001. 
NT-proBNP remained significantly associated with screening-detected AF 
after multivariable logistic regression, p < 0.001. A cut-off of NT-proBNP 125 
ng/L was shown to have a sensitivity of 75% and a negative predictive value 
of 92% for screening-detected AF.  
In study IV, 41 elderly patients (mean 76.3 +/- 5.4 years) with a prior 
ischemic stroke/transient ischemic attack (TIA) and no prior diagnosis of AF 
were included and three methods of AF detection: 24-h Holter, 30-days 
intermittent ECG recording, and an implantable loop recorder (ILR), were 
initiated in parallel after a median of 6.8 +/- 4.3 days. One patient was 
excluded due to a brain tumour. AF was detected in 14/40 patients, 
intermittent ECG detected AF in 1 patient, whereas ILR fared significantly 
better, p < 0.001, and detected all 14 cases. Average time to AF detection 
was 14.7 +/- 11.6 months. 
CONCLUSIONS 
Systematic AF screening detected a significant proportion of screened 
individuals with untreated atrial fibrillation. The degree of initiation of 
stroke-preventive therapy was high, particularly in individuals with newly 
detected AF.  
The biomarker NT-proBNP was shown in two cohort studies to be the only 
biomarker out of five that was significantly associated with incipient AF 
after adjustment for other biomarkers and clinical risk factors.  
Individuals with screening-detected atrial fibrillation had higher levels of 
NT-proBNP.  
In elderly patients with an ischemic stroke/TIA, parallel investigation of 
three methods for AF detection revealed that long-term monitoring using an 
implantable cardiac monitor detected significantly more AF compared to 
shorter time-span methods.   
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1 PREFACE 
During my residency in Internal Medicine, I ended up spending most of my 
time in the stroke unit at Danderyd University Hospital. It struck me that 
so many of the patients had atrial fibrillation, and those that did seemed to 
be much worse off than those that did not.  
The first time many of these patients heard of their atrial fibrillation was 
when they had their stroke; although some already had a diagnosis of 
atrial fibrillation but had not been treated adequately with stroke-
preventive therapy prior to their stroke. Several of these patients either did 
not survive, or ended up severely handicapped by their stroke. As such, I 
came to fear ischemic stroke which rendered so many abruptly disabled, 
changing theirs and their relatives lives forever in just a matter of seconds. 
When Mårten, Viveka & Johan gave me the chance to be involved in a 
study that was trying to find atrial fibrillation and treat it, hopefully 
preventing this fearsome condition, I took it! Since then I have spent a lot 
of time trying to catch this elusive condition, and I can easily say that it 
turned out to be one of the best decisions of my life. 
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2 INTRODUCTION 
2.1 THE BEGINNING- THE HISTORY OF ATRIAL FIBRILLATION 
In November 1909 a preliminary communication was printed in the 
British Medical Journal by the cardiologist Sir Thomas Lewis, 
describing what he called an extremely common condition with a 
completely irregular pulse, often found in patients with mitral stenosis. 
Using the newly invented – by Einthoven – electrocardiogram (ECG), Sir 
Lewis was able to show that the heart rhythm was completely irregular 
and that the rhythm arose from the auricles of the heart. Hence he 
called it auricular fibrillation1, Figure 1.  
 
 
 
Figure 1 Table depicting venous curves (top), arterial curves (middle) and 
electrocardiogram (bottom) of atrial fibrillation by Dr Lewis, reprinted courtesy of 
The British Cardiovascular Society Archives.  
 
The condition had been described prior to Sir Lewis’ paper. Perhaps the 
earliest, and most elegant description comes from The Yellow 
Emperor's Classic of Internal Medicine by Huang Ti Nei Ching Su Wen 
(1696-2598 BC)2. 
 
“When the pulse is irregular and tremulous and the beats occur at 
intervals, then the impulse of life fades; when the pulse is slender 
(smaller than feeble, but still perceptible, thin like a silk thread), then the 
impulse of life is small.”  
 
Huang Ti Nei Ching Su Wen 
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Still, the recording of completely irregular heartbeats of atrial 
fibrillation on an ECG by Dr Lewis formed the basis of today´s 
definition of atrial fibrillation (AF); an ECG documented absolutely 
irregular heart rhythm without discernible p-waves lasting for at least 
30 seconds3. 
2.2 WHAT IS ATRIAL FIBRILLATION – BRIEF OVERVIEW OF 
PATHOPHYSIOLOGY 
In the normally beating heart the sinoatrial node in the right atria acts 
as a pacemaker. It will closely interact with the autonomous nervous 
system to regulate the heart rhythm (sinus rhythm). In atrial 
fibrillation (AF) other foci than the sinoatrial node initiates the heart 
rhythm, and the resulting contractions of the atria become fast and 
erratic causing the atria to fibrillate. The extremely rapid atrial rate is 
slowed down in the atrioventricular node, but the resulting ventricular 
heart rhythm becomes irregular. Common symptoms of AF are 
palpitations, shortness of breath, chest pain, reduced exercise capacity 
and tiredness 2 3. 
 
The pathophysiology of AF is complex and is due to a combination of 
electrical- and structural remodelling in the heart, Figure 2 4. Many 
conditions predispose to the development of AF by inducing structural 
changes in the heart, which helps maintain the arrhythmia. 
Biomarkers measured in the blood can be used to gain insight about 
the pathophysiological changes in the heart. 
 
AF is commonly initiated by electrical foci in the junction between the 
posterior left atria and pulmonary veins. The reason for this loci to 
initiate AF is not completely understood, but the anisotropy of the cells 
at the junction, in combination with atrial stretch, can be a part of the 
cause4. Isolation of the pulmonary veins by means of ablation can be 
used as a mean of preventing new episodes of atrial fibrillation 5. There 
are several explanations for the electrical persistence of the 
arrhythmia, including one ectopic focus, a single re-entry circuit or 
multiple re-entry foci 6. 
 
Once the myocytes in the atria start to beat rapidly, calcium (Ca2+) will 
flow into the cells, which in turn will cause more Ca2+ to be released 
from the sarcoplasmic reticulum (Ca2+-induced Ca2+-release). This large 
burden of intracellular Ca2+ will cause an electrical remodelling 
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involving shortening of the atrial repolarization phase, the atrial 
wavelength and a decrease in refractoriness 7 8. These changes ease 
initiation and help perpetuate the arrhythmia giving rise to the 
expression “AF begets AF”. Even if sinus rhythm is restored, these 
changes will persist for days or weeks (probably caused by alterations 
in the expression of ion channels)9.  
 
The rapid heart rate could cause a mismatch in the oxidative demand, 
and cause oxidative stress and myocardial damage 10. A marker of 
oxidative stress is growth differentiation factor-15 (GDF-15)11 and a 
marker of myocardial damage is Troponin (Tn).   
 
Eventually the Ca2+-overload will lead to a downregulation of Ca2+ -
channels, which in turn will diminish contractility of the atria and may 
lead to structural remodelling in the atria including atrial dilatation. 
The atrial myocytes will adapt to the overload of Ca2+ and metabolic 
stress by starting to heterogeneously hibernate with increasing cell size 
increases and myolysis9.  This myolysis can form the basis of a low 
grade inflammatory state 12, which could be measured using the 
biomarker C-reactive protein (CRP). Inflammatory markers have also 
been shown to be correlated to prothrombotic markers13.  
 
The resulting atrial fibrosis leads to slowing of the electrical 
conduction, isolates the myocytes from each other, and increases the 
possibility of re-entry circuits. The atrial fibrosis can be caused by AF 
in itself, as AF induces increased expression of extracellular matrix 
proteins7, 9, 14. Commonly other illnesses such as heart failure and 
hypertension, or simply old age, cause atrial fibrosis by 
volume/pressure overload in the atria. When atrial cardiac myocytes 
are subjected to stretch, they will secrete a pro-peptide brain 
natriuretic peptide (BNP) 15 which will be split in equal proportions into 
the biologically active BNP and the inert biomarker N-terminal (NT)-
proBNP. The active BNP will try to reduce volume overload by increased 
diuresis, vasodilatation and decreased renin and aldosterone secretion 
16.  
 
Activation of the renin-angiotensin-aldosterone (RAAS) pathway is 
common in renal failure and might contribute to AF by increasing atrial 
fibrosis 17. Cystatin C is commonly used as a biomarker of renal 
dysfunction.  
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There are several common genetic variants which increase the 
susceptibility of AF, and in young individuals with AF there can be a 
strong hereditary component 3. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2 –  The vicious circles involved in AF pathophysiology depicting the disease’s 
multifactorial nature. Focal activity within the pulmonary veins can be caused by 
stretch, spontaneous calcium release and sympathetic stimulation. The fast atrial 
rates cause intracellular Ca2+-overload, which then initiates electrical remodelling. 
Activation of the RAAS-system will cause many of the structural changes in the atria. 
Rapid heart rate can cause left ventricular dysfunction, leading to further activation 
of the RAAS-system and increased sympathetic activation. The figure has been 
modified by the author of the thesis by addition of biomarkers that could potentially 
represent the pathophysiological pathways, and by removal of therapeutic options. 
Koebe J, Kirchhof P. Novel non-pharmacological approaches for antiarrhythmic 
therapy of atrial fibrillation, Europace 2008. Reprinted with permission. 
2.3 WHO HAS ATRIAL FIBRILLATION – PREVALENCE 
Sir Thomas Lewis described AF as extremely common 1 and with more 
than 30 million people affected worldwide 18, 19, this is not an 
understatement. In Western populations the adult prevalence ranges 
between 1% and 3% 20 21, Friberg, 2013 #15, 22. Data is more limited with 
regards to prevalence in Africa, Asia and South America 18.  
 
Cystatin- C 
NT-proBNP 
Troponin 
CRP 
GDF-15 
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Several other concomitant cardiac and medical conditions increase the 
risk of AF and in these patient categories, AF prevalence is higher. 
Examples of conditions affecting the risk of getting AF are: heart 
failure, hypertension, valvular heart disease, myocardial infarction, 
thyroid disease, obesity, diabetes mellitus, chronic obstructive 
pulmonary disease and renal failure 3.  
 
There is a steep increase in AF prevalence in the elderly population20 
whereas individuals below the age of 55 are rarely affected (0.1%). This 
is in contrast to the high prevalence of AF in the elderly with 9% 
affected in >80 years 21. 
With an ageing population, AF prevalence is expected to double within 
the next 50 years in both Europe & the US 23 24, Figure 3.  
 
 
Figure 3 Solid line shows projected prevalence of AF in the United States 
assuming no increase in age-adjusted AF incidence. Dotted curve shows AF 
prevalence if age-adjusted AF incidence continue to increase as between 1980-
2000.  
Miyasaka Y et al., Secular trends in incidence of atrial fibrillation in Olmsted 
County, Minnesota, 1980 to 2000, and implications on the projections for future 
prevalence,  Circulation 2006; 114: 119-125. Reprinted courtesy of Wolters 
Kluwer Health Inc. 
 
The variation in reported AF prevalence may be due to a number of 
factors, including divergent risks in populations 21 , 25, a varying grade 
of access to health care in the society and the possibility to conduct 
epidemiological studies. In addition, up to one third of patients AF are 
asymptomatic 26. These patients are less likely to get a diagnosis of AF 
as they do not seek health care. Furthermore, many patients have AF 
that is intermittent (paroxysmal)27 and might not have the arrhythmia 
at the time of contact with health care.  
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The combination of a commonly asymptomatic and intermittent 
arrhythmia is likely to underestimate the prevalence of AF. 
 
AF is clinically categorized into five different categories depending on 
duration, clinical presentation and aim of treatment, Figure 4 3. 
Figure 4 Atrial fibrillation is classified according to clinical presentation, duration, 
and therapeutic aim into 5 different categories. AF= Atrial Fibrillation SR=sinus 
rhythm 
 
2.4 WHY LOOK FOR ATRIAL FIBRILLATION?  
The loss of proper atrial contractions in the heart during atrial 
fibrillation leads to a hypercoagulable state where thrombogenic factors 
are expressed more commonly 28 3 and stasis of blood can occur in the 
atria, especially in the left atrial appendage, promoting blood clots. 
These blood clots can then migrate to the brain 29 and cause a stroke.  
 
Patients with AF have a 5-fold increase in the risk of getting a stroke 29, 
and the large blood clots dislodging from the heart will cause more 
severe strokes; patients with AF have doubled mortality and higher 
disability compared to patients without AF 30. 
 
This risk can be ameliorated using oral anticoagulant (OAC) therapy, 
which is beneficial in the majority of AF patients, reducing the risk of 
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stroke by at least 64% 31. In order to assess stroke risk in AF patients a 
clinical risk score was recommended in the European Society of 
Cardiology (ESC) guidelines from 201032 using the acronym CHA2DS2-
VASc, Table 1.  
 
 Points 
awarded 
 CHA2DS2-VASc  
score 
Stroke and TE event rate  
at 1 year follow-up (%) 
Congestive Heart Failure  
 
1  0 0.78 
 
Hypertension 1  1 2.01 
 
Age, 75 and above 2  2 3.71 
 
Diabetes Mellitus 1  3 5.92 
 
Stroke/TIA/TE 2  4 9.27 
 
Vascular disease 1  5 15.26 
 
Age, 65-74 1  6 19.74 
 
Sexual category (female) 1  7 21.50 
 
Maximum score 9  8 22.38 
 
   9 23.64 
 
Table 1 The CHA2DS2-VASc risk score for assessing stroke risk in patients with atrial 
fibrillation, and the yearly rate of stroke and thromboembolic rate according to 
CHA2DS2-VASc score. Vascular disease defined as prior myocardial infarction, 
peripheral artery disease or aortic plaque. TIA= transient ischemic attack TE= 
thromboembolism 
Camm AJ, et al. 2012 Corrigendum to focused update of the ESC Guidelines for the 
management of atrial fibrillation. European heart journal 2012, by permission of 
Oxford University Press.   
 
The CHA2DS2-VASc score can be used to guide treatment decision, and 
in general men with CHA2DS2-VASc ≥ 2 and women with CHA2DS2-
VASc ≥3 should be recommended OAC treatment after assessment of 
bleeding risk, whereas an individualized decision should be made in 
men with CHA2DS2-VASc 1p and women with 2p 3. Recent studies have 
shown that biomarkers could help assess the risk of stroke in AF 
patients. That might be clinically useful in the future 33.  
Despite the fact that OAC therapy is highly efficient for stroke-
prevention in patients with AF, underuse is common, especially in high 
risk groups 34. With the addition of new oral anticoagulants and clear 
guidelines there has been improvement 35, 36.  
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The clinical presentation of the patient, that is the type of AF, and 
whether the patient is symptomatic or not, is not taken into account 
when assessing stroke risk 3.  
 
Prior studies have shown a similar stroke risk in patients with 
paroxysmal and permanent AF 37, 38; however, emerging evidence from 
meta-analysis of the large trials of novel oral anticoagulants (NOACs) 
shows that although the risk of stroke in paroxysmal AF is high, the 
risk might be even higher in persistent and permanent AF39.  
 
In Olmsted county 476 patients with incident AF were followed for a 
median of 5.6 years, and the 161 (34%) that were asymptomatic on 
presentation had an almost 3-fold increased risk of stroke/TIA 
compared to AF patients who presented with palpitations 40, Figure 5.   
 
Figure 5 Cumulative incidence curves for survival free of incidence of stroke/TIA 
by type of AF presentation. Siontis et al. Typical, atypical, and asymptomatic 
presentations of new-onset atrial fibrillation in the community: Characteristics 
and prognostic implications. Heart Rhythm, 2016 Reprinted with permission 
from Elsevier 
 
In the EurObservational Research Programme (EORP) Pilot general AF 
registry, 3,119 patients were included, 39.7% of whom were 
asymptomatic. Asymptomatic patients had higher 1-year mortality 
compared to symptomatic patients 41. 
 
In another study 5,555 patients with incidentally diagnosed AF were 
shown to have a stroke incidence more than twice as high when 
compared to age and gender matched controls without AF 42. The use 
of oral anticoagulants reduced mortality in the group with incidentally 
diagnosed AF by >40% and the risk of stroke by >60%.  
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Pacemakers with an atrial lead can help identify atrial high rate 
episodes (AHREs). Patients where AHREs have been detected have an 
increased risk of stroke 43, albeit this risk is lower than the risk in 
patients detected with other means 43. Currently the ESC 
recommendation is to interrogate pacemakers for the presence of 
AHREs, and then verify it by ECG 3. Two ongoing studies, ARTESiA 
(NCT01938248) and NOAH – AFNET (NCT02618577) will test the 
usefulness of treatment with OAC in patients with AHREs. 
 
2.5 SCREENING FOR ATRIAL FIBRILLATION IN THE POPULATION 
Screening for AF was introduced in the ESC guidelines in 201244 in 
order to reduce stroke-related morbidity in AF.  The recommendation 
for opportunistic screening in individuals aged 65 and above, using 
pulse palpation followed by an ECG is based on the only randomized 
study that has compared screening versus routine practice - the SAFE 
study45. This three-armed study was performed in individuals in the 
UK aged 65 and above and investigated the difference in AF detection 
using opportunistic or systematic screening versus routine practise. 
Opportunistic screening means that screening is performed in 
individuals seeking health care for other reasons, whereas systematic 
screening an entire segment of the population will be invited to attend 
a screening program. The study showed that pulse palpation detected 
1.6% undiagnosed AF in both the systematic and the opportunistic 
arm, and both were shown to be more efficient than routine practice in 
finding AF. Opportunistic screening was shown to be cost-effective 46.   
 
However, pulse palpation is limited by a low specificity 47 and has to be 
followed by an ECG to confirm diagnosis, which can hamper the 
detection of AF 48.  
 
Other screening studies have looked at the yield of newly detected AF 
when using single time-point screening, and they have been 
summarized in a meta-analysis49 showing that when screening a 
population aged 65 and above, 1.4 % would be diagnosed with new AF. 
Single-time point screening will likely detect non-paroxysmal forms of 
AF. In order to identify paroxysmal forms of AF, screening might need 
to be continued for prolonged periods of time.  
 
With new technology, several new devices have emerged that can 
increase ease and accuracy of AF diagnosis. These devices generally 
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record an ECG in lead I, and have a high sensitivity and specificity for 
AF detection, Table 2. Despite being ambulatory the majority have only 
been used in single-time point screening.
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 Device 
 
Sensitivity 
Specificity 
 
First author, 
journal, year 
Number 
of leads 
/duration 
Type Population
/Setting 
Country Type of 
Screening 
Minimum 
age 
Mean 
age 
Screening 
detected 
AF 
 My Diagnostic  
Sens 100 
Spec 96 50 
Kaasenbrood, 
Europace, 
201651 
1/1 min Single 
time-point 
3,269 
Influenza 
clinic  
Holland Opportunistic NA 69.4 1.1 % 
 AliveCor  
Sens 98 
Spec 97 
52 
Lowres, 
Thromb 
Haemost, 
201453 
1/30-60 
sec 
Single 
time-point 
1 000 
Pharmacy 
customers 
Australia Opportunistic 65 76 1.5% 
 Zenicor  
Sens 96 
Spec 92 
54 
Engdahl, 
Circulation 
2013 
55 
1/30 sec Twice 
daily for 
14 days 
403 
Screening 
clinic  
Sweden Systematic 
(step wise) 
 
75 75/76 7.4% 
 Pulse-palpation  +12 lead ECG 
 Fitzmaurice 
45 
30 sec Single 
time-point 
4,575 
GP 
UK Opportunistic 
arm 
65 75.1 1.64 % 
      4,562 GP 
UK Systematic 
arm 
65 75.2 1.62% 
 
Table 2 AF screening using different ambulatory1-lead devices compared to pulse-palpation Sens= Sensitivity Spec= Specificity   
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In a step-wise systematic screening study performed in 75/76-year 
olds in Sweden, 1,330 individuals were invited to screening, and 848 
(64%) attended 55. All participants were asked to perform a 12-lead 
ECG, leading to AF detection in 10 (1%) subjects. Participants with one 
additional risk factor for stroke (heart failure/hypertension/diabetes or 
prior stroke/TIA), n=403, were offered prolonged screening for AF using 
intermittent ECG recordings twice daily for 14 days. New AF was 
detected in 30 (7.4%) participants.  
Patient-activated intermittent ECG devices only monitor the heart 
rhythm a fraction of the time, and paroxysmal AF episodes might still 
be missed. Compared to 24-h Holter monitoring 30-days intermittent 
ECGs was shown to be more sensitive in detecting AF 56, whereas 5-
days Holter identified a proportionate amount of AF 57. The ease of use 
makes intermittent ECG devices a good tool for AF detection.  
 
With the ongoing technological development, newer methods for AF 
detection might monitor the heart rhythm continuously. One example 
of this is a wearable patch that was used for 14 days in a smaller study 
of 75 males aged above 55, and AF was detected in 4 (5.3%)58.  
 
Many more methods for AF detection are currently underway, for 
instance oscillometric blood pressure monitors measuring pulse 
irregularity 59 and smart phone photoplethysmograpy 60, but for AF 
diagnosis, an ECG continues to be required.  
2.6 BIOMARKERS IN ATRIAL FIBRILLATION 
The diagnosis of many clinical conditions are guided by measurement 
of biomarkers in the blood 61, 62. For atrial fibrillation the clinical value 
of biomarkers has great potential, as they might add insight into 
pathophysiology, and perhaps help risk stratification, but as of yet they 
are not used in clinical practise. In cohort studies many different 
biomarkers have shown an association with AF 63.   
 
The cardiac biomarker NT-proBNP released in response to atrial 
myocyte stretch has in cohort studies been associated with incident AF 
64-68. The NOAC studies ARISTOTLE and RELY encompassing AF 
patients treated with anticoagulation therapy showed that individuals 
with high NT-proBNP levels had an increased risk of stroke 69 70. In a 
meta-analysis of patients with a prior stroke, NT-proBNP was one of 
the main predictors for cardio-embolic stroke 71. In a smaller study of 
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244 individuals screened for AF using 7-days Holter monitoring, 
BNP/NT-proBNP showed high predictive ability of AF 72. 
 
The marker of cardiac myocyte damage, Troponin, has in several cohort 
studies been shown to be associated with AF 73 74, but the association 
was less strong, when adjusting for other biomarkers (CRP and BNP) 
75. In the RE-LY and ARISTOTLE trials high-sensitivity troponins have, 
like NT-proBNP, been associated with stroke 70 76. 
 
The biomarkers NT-proBNP and troponin have been suggested to be 
used to assess the risk of stroke in AF patients in a new risk score 
(ABC-score) 33. 
 
The biomarker GDF-15 is a marker of oxidative stress, inflammation 
and cellular ageing, but its receptor and signalling pathways remain 
unknown 77. In a smaller study of patients with paroxysmal AF, GDF-
15 was shown to be increased 78 but in larger cohort studies GDF-15 
was not shown in adjusted analysis to be associated with AF or stroke 
77, 79. In anticoagulated patients with AF, GDF-15 has been shown to be 
a marker of bleeding risk 77 and has been suggested for use in a new 
bleeding score 80.  
 
In the majority of cohort studies, the inflammatory marker CRP has 
shown an association between AF and CRP, although not always a 
consistent one 66 81 82. Inflammatory markers have been shown to be 
associated with prothrombotic markers 13.  
 
Cystatin C is commonly used as a marker of renal dysfunction.  
Chronic renal failure has been shown in a recent meta-analysis to be 
associated with onset of atrial fibrillation 83, and patients with end-
stage renal failure have a higher prevalence of AF and an increased risk 
of stroke 84 85. Patients with renal failure also have a higher risk of 
bleeding, a factor that has been addressed in the HAS-BLED bleeding 
score 86. 
 
2.7 IS AF SUITABLE FOR SYSTEMATIC SCREENING?  
 
The earliest known example of screening was initiated in 1917 when 
American army recruits were subjected to intelligence tests in order to, 
“help to eliminate from the Army at the earliest possible moment those 
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recruits whose defective intelligence would make them a menace to the 
military organisation’’ 87.  
 
This is different from the perception of screening today where it is used 
in populations perceived as healthy in order to detect hidden illness 
that can be treated in order to avoid future consequences 88. The 
benefits of screening are on a population level, and it is important that 
the screening test is not perceived as uncomfortable to the individual. 
In 1968 the World Health Organization published criteria for screening 
89. AF fulfils most of these, Table 3. 
 
 WHO criteria Applicability for AF screening 
1 The condition sought should be an important health problem 
The prevalence of AF is high20, and AF 
increases the risk of stroke 5-fold 3, 29 
2 There should be an accepted treatment for patients with recognized disease 
Major guidelines agree that the majority of 
patients should be treated with oral 
anticoagulant therapy 3, 90 
3 Facilities for diagnosis and treatment should be available 
Several methods for easy diagnosis of AF 
exist, and can easily be carried out at 
existing health care, or new facilities can be 
arranged. Treatment is already part of the 
general health care.  
4 There should be a recognizable latent or early symptomatic stage 
AF can start as an asymptomatic condition, 
and then progress into paroxysmal, 
persistent or permanent forms of AF91. The 
risk of ischemic stroke is high in all forms of 
AF38.  
5 There should a suitable test or examination A single time-point ECG can be recorded to detect non-paroxysmal AF49. Prolonged 
screening might be needed for paroxysmal 
AF. 
6 The test should be acceptable to the population 
 
An ECG causes no harm and is non-
invasive. 
7 The natural history of the condition, including 
development from latent to declared disease, should 
be adequately understood 
There is a general consensus that AF causes 
stroke3. The burden of AF needed to 
increase cardio-embolic risk is not known. 
8 There should be an agreed policy on whom to treat as 
patients 
There are clear guidelines on treatment3, 90. 
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9 The cost of case finding (including diagnosis and 
treatment of patients diagnosed) should be 
economically balanced in relation to possible 
expenditure on medical care as a whole 
Cost-efficacy studies have been performed 
showing high cost-efficiency 92. 
10 Case finding should be a continuing process and not 
a ‘once and for all’ project 
 
The most efficient way of AF detection is 
not yet known and needs further study. 
Table 3 World Health organizations criteria for screening, and the applicability of AF 
screening.  
 
2.8 SCREENING FOR ATRIAL FIBRILLATION IN STROKE PATIENTS  
 
One early morning in the emergency room I met a patient who woke up 
with a stroke, and was extensively impaired with aphasia and 
hemiplegia. This patient recovered quite miraculously after an 
emergency thrombectomy. I was convinced that this patient might have 
AF, but initial screening using 24-hour Holter monitoring did not reveal 
arrhythmia.  
 
The prevalence of AF in patients who have already suffered from an 
ischemic stroke is high; in Swedish registry studies, > 30% of patients 
suffering an ischemic stroke have AF 93 94. Patients with ischemic 
stroke and untreated AF have a high risk of suffering a new stroke 95 
44.  
 
In the European stroke organization guidelines from 2008, a 24-hour 
Holter monitoring is recommended to screen for AF post-stroke 96. This 
method has been shown to be inferior to other means of screening, for 
instance 30 days intermittent ECG registration 97, 72-hour Holter 
monitoring 98 and 30 days’ continuous event-recorder 99. These studies 
formed the basis for a change in the American Heart Association 
guidelines for the management of stroke 2014 which now recommend 
prolonged rhythm monitoring (30 days) within 6 months of a 
TIA/stroke 100.  
 
In the CRYSTAL-AF trial, 441 stroke/TIA patients with no known cause 
of their stroke were randomized to implantation of an implantable 
cardiac monitor (ILR) or conventional follow-up 101. In the group who 
had an ILR, AF was found in 8.9% within 6 months compared to 1.4% 
in the control group.  
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One meta-analysis of >5000 patients with a prior stroke/TIA 
undergoing at least 12 hours cardiac monitoring showed a detection of 
11.5% AF in unselected stroke patients 102. In a second meta-analysis 
in which a step-wise approach for AF detection was applied, >20% was 
discovered 103.   
 
The ESC guidelines for AF of 2016 recommend that patients with TIA 
or ischaemic stroke should be screened for AF using short-term ECG 
recording followed by continuous ECG monitoring for at least 72 
hours3. But it also adds that, “for stroke patients additional ECG 
monitoring by long-term non-invasive ECG monitors or implanted loop 
recorders should be considered to document silent atrial fibrillation”. 
 
How did my patient in the emergency room do? In the end I managed 
to include this patient in study IV, and AF was detected using an 
implantable loop recorder. This patient is currently on OAC therapy 
and has not suffered another stroke event. 
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3 AIMS 
OVERALL AIM 
To study the feasibility of systematic screening for atrial fibrillation in 
populations with high risk for ischemic stroke and to validate if the 
addition of biomarkers can improve the efficacy of such screening. To 
explore the value of monitoring the heart during different time periods in 
patients who have had a stroke/TIA. 
 
STUDY I   
To study the feasibility of systematic screening for AF in a high-risk 
population using prolonged intermittent ECG screening and to study the 
prevalence of AF as well as, the prevalence of patients with inadequately 
treated AF.  
To assess the possibility of OAC initiation in screening-detected atrial 
fibrillation. 
 
STUDY II  
To study the association between incident AF and five biomarkers 
representing different pathophysiological pathways, NT-proBNP, high 
sensitivity (hs)-Troponin, hs-CRP, GDF-15 and Cystatin-C, individually or 
in combination, in addition to cardiovascular risk factors in two cohorts. 
 
STUDY III 
To evaluate the most potent biomarker from study II (NT-proBNP) in 
systematic screening for AF, in order to establish if there is a difference in 
levels of NT-proBNP in participants where AF is detected in screening 
compared to participants where AF is not detected. To assess if NT-proBNP 
could be used to predict which individuals that may benefit from AF-
screening. 
 
STUDY IV  
To study which of three different methods, 24-h Holter ECG, 30-days event 
recorder and implantable loop recorder (ILR), that when applied in parallel, 
will detect most AF in elderly patients with a recent ischemic 
stroke/transient ischemic attack (TIA). 
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4 MATERIAL AND METHODS 
STUDY I & III 
In the Strokestop study all individuals born in 1936 or 1937, living within 
two Swedish regions were identified by their civic registration numbers. 
After stratification for gender, year of birth and region, a 1:1 randomization 
was performed. All individuals randomized to screening were invited per 
letter to attend an AF screening clinic. Non-responders in Stockholm 
received two reminders and in Halland 1 reminder. Individuals who had 
passed away before or during the invitation process were identified and 
excluded, see Figure 6. 
 
Figure 6 Participation in the Strokestop study. Reprinted courtesy of Circulation: 2015;131(25) 
Wolters Kluwer Health Lippincott Williams & Wilkins© 
After signing informed consent self-reported medical history, use of 
antiplatelet and anticoagulant medication was obtained. Participants in 
Stockholm were asked to self-assess their weight and height. All 
participants without a known diagnosis of AF, and who were free from AF 
on their first ECG, were instructed on how to perform a handheld 1-lead 
ECG twice daily for a fortnight. The handheld ECG device from Zenicor, 
Figure 7, records a 30-sec ECG and sends it through mobile technology to a 
database. 
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Figure 7 – Handheld ambulatory ECG device - Image courtesy of Zenicor  
The device has high sensitivity and specificity for detection of AF 54, 56. AF 
was defined as one episode of irregular heart rhythm without p-waves 
lasting for 30 seconds, or at least two such episodes lasting 10-29 seconds. 
Specially trained research nurses reviewed all ECGs, and all pathological 
ECGs were referred to the investigators. Participants with a new diagnosis of 
AF, or a previous diagnosis of AF if inadequately treated, were referred to a 
cardiologist for follow-up, including initiation of OAC-therapy after 
assessment of contraindications. Participants with other arrhythmias were 
followed-up as appropriate. In subjects with ECGs hampered by baseline 
disturbances or uncertainty regarding diagnosis, additional long-term ECG 
was performed.   
In addition, in the last 815 consecutive participants attending screening a 
sample of NT-proBNP was taken and analysed bedside using a point of care 
analyser (Cobas 232 point-of-care), and 71 individuals with newly detected 
AF had NT-proBNP taken at cardiology follow-up (Immulite 2000 XPI). The 
results from this analysis of NT-proBNP is presented in paper III. 
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STUDY II 
Two large cohorts of elderly citizens residing in Uppsala, The Uppsala 
Longitudinal Study of Adult Men (ULSAM) and The Prospective Investigation 
of the Vasculature in Uppsala Seniors (PIVUS), were studied. The year of 
baseline-investigation, the participant’s age, and gender is depicted in 
Figure 8. Biomarkers of from five different pathophysiological pathways 
were obtained; N-terminal pro-B-type Natriuretic Peptide (NT-proBNP) 
indicative of atrial stretch, high-sensitive (hs) Troponin (Tn) as a marker of 
myocyte damage, Growth Differentiation Factor -15 (GDF-15), which is a 
marker of oxidative stress, the renal biomarker cystatin C and the 
inflammatory marker hs C-reactive protein (CRP).  Participants without 
plasma samples or a known diagnosis of AF were excluded.  
 
Figure 8 Participants in the two cohort studies 
At the baseline visits, baseline data with regards to cardiovascular risk-
factors were assessed, Figure 8. A diagnosis of diabetes mellitus was made if 
fasting plasma glucose levels were above 7.0 mmol/L or diabetic medication 
was used. Venous blood samples were drawn and stored at −70°C. 
The primary endpoint was first diagnosis of AF using data collected from the 
National Board of Health and Welfare in Sweden, where all deaths and 
hospitalizations in Sweden are registered with International Statistical 
Classification of Diseases and Related Health Problems (ICD) codes and 
dates. Median follow-up time was 12.6 (range 0.0–20.4) years in ULSAM and 
10.0 (range 0.3–10.9) years in the PIVUS cohort.  
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BIOCHEMICAL ANALYSIS 
The analysis of NT-proBNP was made using a sandwich immunoassay 
(Roche Diagnostics) on an Elecsys 2010 instrument. Using the Cobas 
Analytics immunoanalyzers (Roche Diagnostics) hs-cardiac (c) troponin 
(Tn)T was analysed in the ULSAM study. In the PIVUS cohort, hs-cTnI was 
analysed using a high-sensitivity assay on an ARCHITECT i1000SR (Abbott 
Laboratories, Abbott Park, IL). GDF-15 (Roche Diagnostics) was measured 
using a monoclonal mouse antibody for capture and a monoclonal mouse 
antibody fragment (F(ab′)2) for detection in a sandwich assay format. 
Cystatin C was detected with the Architect system ci8200 (Abbott 
Laboratories, Abbott Park, IL) using the particle-enhanced turbidimetric 
immunoassay from Gentian (Gentian, Moss, Norway). The Grubb equation 
(eGFR = 86.49 × pCY − 1.686 × 0.948 [if female]) was used to estimate 
glomerular filtration rate (eGFR) from Cystatin C. A latex enhanced reagent 
(Dade Behring, Deerfield, IL) on a Behring BN ProSpec analyser (Dade 
Behring) was used to measure hs-CRP. 
Samples were stored, and all biochemical analyses were performed at the 
Uppsala Clinical Research Center laboratory (Uppsala, Sweden). 
 
  
 30 
STUDY IV 
Patients with ischemic TIA/stroke, n=41, without known AF aged 65 and 
above, were included at one university hospital (Danderyd) and one regional 
hospital (Varberg) in Sweden. The patients were included within 14 days of 
their ischemic event. Subjects with contraindications to OAC therapy, 
patients unable to perform intermittent ECG recordings, and patients not 
able to give informed consent were excluded. Usual standard of care, 
including brain imaging and visualization of the carotid arteries was given to 
all patients. For initial symptoms the National Institutes of Health Stroke 
Scale (NIHSS) was assessed in the majority of patients but was lacking in 8 
patients and was estimated after review of charts by one investigator. 
All included patients had an implantable loop recorder (ILR) (Medtronic 
Reveal XT) implanted, Figure 9, and in parallel 24-hour Holter monitoring 
and twice daily 30 second 1-lead intermittent ECG recordings (Zenicor) for 
30 days was initiated, Figure 7.  
Figure 9 Implantable loop recorder (ILR) Medtronic Reveal XT. Reproduced with 
permission of Medtronic, Inc. 
Weekly follow-up was arranged during the first month of the study. 
Thereafter ECG recordings were sent monthly from their implantable loop 
recorder through a home-monitoring system (Care-Link) during the first 
year. All patients were offered yearly follow-up visits, unless they had 
symptoms, or ECG abnormalities requiring earlier visits. After the first year 
patients were offered to continue quarterly transmissions. All patients who 
had AF detected were offered OAC therapy. 
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4.1 STATISTICS  
4.1.1 GENERAL 
For all statistical tests and confidence intervals, two-sided tests were used, 
and a p-value of <0.05 was considered significant. Continuous variables 
were visually inspected using histograms for assessment of normal 
distribution. In addition to this, Shapiro-Wilks test was used. Continuous 
variables are reported as mean±standard deviation (SD) or 
median±interquartile range (IQR).  
For the non-normal distributed biomarkers in study II, logarithmic scale 
was used if a normal distribution was achieved; otherwise, quartiles or 
tertiles were used as categorical variables.   
For continuous normally distributed variables, the Student t test was used. 
For proportions, the Fisher exact test or chi-square tests were used as 
appropriate. Non-parametric data were analysed using Mann-Whitney U or 
Kruskal-Wallis test.  
In study I & III multivariable analysis with binary outcomes was performed 
using logistic regression. For discriminative abilities of the model, see 
section on risk scores (below).  
In study II, Cox proportional hazard regression models were used, and the 
results for continuous predictors are presented as estimated hazard ratios 
with 95% confidence intervals for one standard deviation increase of the 
predictor. For categorical variables the effect of change was shown from a 
reference category.  
In study III, when analysing NT-proBNP cut-off, the data was split into two 
randomized groups using frequency matching based on diagnosis of new 
AF. Visual inspection of receiver operating characteristic regression (ROC)-
curves was used to assess a cut-off value of NT-proBNP for one of the 
groups, which was subsequently verified in the other group. 
In study IV the NIHSS parameter was dichotomized into a group with NIHSS 
≤3 and NIHSS ≥4. In study III we compare three different methods, using a 
Cochran’s Q test. When comparing two different models McNemar’s test was 
used. AF detection rate was plotted using Kaplan-Meier curves, and 
censoring was performed at time of ILR explantation, death or end of follow-
up.  
4.1.2 POWER CALCULATIONS  
STUDY I-IV 
The first study is a cross-sectional study showing the prevalence of atrial 
fibrillation in the 75/76-year old population in two Swedish regions. For a 
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cross-sectional study, no power calculation is needed. Study II is a cohort 
study, hence no power calculation was performed, study III was explorative, 
and study IV was a pilot study. 
4.2 RISK SCORES 
In study I-III the use of risk scores is assessed. One of the corner stones of 
medicine today is the use of risk scores to predict risk of a certain event, for 
instance stroke risk in patients with AF, and to guide therapy to ameliorate 
that risk 3. A risk prediction tool is evaluated by discrimination and 
calibration 104. The discrimination is the ability of the risk score to correctly 
discern individuals who will develop the disease and those who won’t. The 
receiver operating characteristics curve is used to as a graphical tool to 
illustrate the performance of the discriminative abilities of a test.  
The discriminative ability of a risk score can be studied using the area 
under the curve (AUC) of receiver operating characteristics (ROC) curves, 
also called C-statistic, Figure 10. 
 
Sensitivity 
 
 
 
Figure 10 – Model of a receiver operating characteristics curve (ROC-curve) with the 
dotted line showing a test no better than chance, and the orange line depicting a test 
with fairly high predictive ability 
However, the discriminative abilities of C-statistics has shown to be limited 
when small changes that might be of clinical relevance, for instance the 
addition of new biomarkers to existing risk scores, have been evaluated 105. 
Therefore, other methods have been proposed to study the incremental 
value of biomarkers to existing risk scores such as: 
Net reclassification index (NRI) which is based on the ability of the new 
model to reclassify individuals.  
NRI = (Proportion of correctly reclassified with an event - Proportion of wrongly 
reclassified with an event) +  
(Proportion of correctly reclassified without an event - Proportion of wrongly 
reclassified without an event) 
False positive (1-specificity) 
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The first part of the equation describes an improvement in sensitivity, and 
the second part an improvement in specificity. An NRI of 0.15 would mean 
that 15% had an improved classification with no net loss for subjects 
without event.  
Integrated Discrimination Improvement (IDI) describes improvement of 
average (integrated) sensitivity without sacrificing average specificity. 
IDI= (Average sensitivity new model - average sensitivity old model) – 
(Average 1-specificity (false positive) new model - Average 1- specificity old 
model) 
If no changes are made in specificity, IDI reflects the changes in average 
sensitivity. 
These methods also have limitations, especially when there are more risk 
categories than two. The interpretation can also be difficult 106.  
Calibration deals with the goodness-of-fit of the model, i.e. the ability of the 
model to predict the number of events in a population over a certain time 
period. It will contrast the number of events that did happen with the 
number of events that were expected to happen over a time period. The 
Grønnesby-Borgan test was used to test calibration of the Cox regression 
analysis.  
The Cohorts for Heart and Aging Research in Genomic Epidemiology 
(CHARGE) have created a simplified risk score for AF using the ten clinical 
characteristics: age, race, weight, height, systolic and diastolic blood 
pressures, antihypertensive therapy, smoking, diabetes mellitus, heart 
failure and myocardial infarction 107. 
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4.3 ETHICAL CONSIDERATIONS 
All studies conform to the Ethical guidelines of the 1975 Declaration of 
Helsinki. Written informed consent was obtained from all participants in 
all four studies. Ethical committees approved all studies prior to study 
start.  
In study I (DNR 2011-1363-31/3), screening is used to detect atrial 
fibrillation. It is not known if the risk of stroke in patients with AF detected 
by intermittent screening is similar to patients with AF detected in the 
clinic, but prior studies of patients with asymptomatic AF show a high risk 
of ischemic stroke 40, 42. The majority of patients with newly diagnosed AF 
were initiated on OAC-treatment, a treatment that has been shown in 
meta-analysis to increase bleeding risk with an incidence of 2.1/100 
patient years for vitamin-K antagonists 108. However in the majority of 
patients with AF, the risk of ischemic stroke outweighs the risk of 
bleeding, and there is a net benefit of OAC-therapy 109. To summarize, the 
stroke-preventive effect of the therapy was perceived as higher compared to 
the risk of bleeding in patients with screen-detected AF, and hence it felt 
that it would have been unethical not to treat these patients with OAC-
treatment.  
It is possible that patients undergoing intermittent screening for two weeks 
become more aware that they might suffer from an arrhythmia, and this 
awareness might cause discomfort. Some patients were referred for further 
long-term ECG registrations, which might have caused additional concern. 
However, all patients that were diagnosed with an arrhythmia received 
prompt care, and in contrast to screening for some diseases like aortic 
aneurysm where patients might be informed that they need to be followed 
on a yearly basis, but that there is no acute indication for therapy, all our 
patients were eligible for therapy immediately after discovery. Patients 
might have been lulled into a false sense of security that they might be free 
from arrhythmia, when in fact the device only monitors heart rhythm a 
fraction of the time.  
In study IV (DNR 2007/386-21/2) all patients had an implantable cardiac 
monitor inserted. This could potentially cause infection at the site of 
surgery as well as discomfort. All patients were informed that the ILR 
could be removed at any time, and as they had recently had a stroke/TIA 
the potential benefits of finding a treatable cause to prevent a new 
ischemic event was deemed as higher than the potential discomfort of 
minor surgery.  
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5 RESULTS – PER STUDY 
5.1 STUDY I 
Participation in the systematic mass-screening program was 53.8% 
(7,173/13,331), and 218 patients (3.0 %, 95% confidence interval [CI], 2.7–
3.5) got a new diagnosis of AF, Figure 11. In the 666 (9.3%, 95% CI 8.6–
10.0) participants with known AF, 149 (2.1%; 95% CI, 1.8–2.4) were not on 
OAC-treatment.  
In total 5.1% (95% CI, 4.6–5.7) of the screened population had untreated 
AF. OAC treatment was initiated in 93% of individuals with new AF, and in 
total 3.7% (95% CI, 3.3–4.2) of the screened population. The main reason for 
not initiating OAC treatment was patient preference. The prevalence of AF 
increased from 9.3 to 12.3%.  
 
 
Figure 11 Results of AF screening in the STROKESTOP study 
A new diagnosis of AF on first ECG was made in 37 individuals (0.5%). The 
majority of patients were diagnosed with AF during the first week of the two-
week registration period, Figure 12. The mean number of AF episodes was 
4.5 (95% CI, 3.4–5.6).  
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Figure 12 Time until detection of first episode of AF among participants undergoing 
AF screening using intermittent ECG recordings. Reprinted courtesy of Circulation: 
2015;131(25) Wolters Kluwer Health Lippincott Williams & Wilkins©  
The group with screening-detected AF had significantly more vascular 
disease, were more commonly male, were taller and heavier compared to the 
group where AF was not detected. The strongest predictor for any AF in a 
multivariable analysis was the presence of congestive heart failure with an 
odds ratio (OR) of 7.19 (95% CI 5.18–9.98, p < 0.001), previous stroke/TIA 
OR 2.27 (95% CI 1.78–2.9, p < 0.001), diabetes mellitus OR 1.46 (1.14–1.86, 
p < 0.001), height per 1 cm increase 1.03 (1.02–1.05, p < 0.001) and weight 
per 1 kg increase OR 1.01 (1.01–1.02, p < 0.001). In women with a body 
mass index (BMI) <25 kg/m2, only 1.3% AF was detected by screening.  
5.2 STUDY II 
During a median follow-up time of 13 years in the ULSAM study 113 
(12.8%) individuals had developed AF, and in the PIVUS study with a 
median follow-up of 10 years 148 (15.1%) developed AF. In both cohorts, 
participants with incident AF were more often treated with antihypertensive 
therapy and had lower total cholesterol at baseline. In adjusted analysis 
antihypertensive medication remained associated with incident AF, Table 4.   
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Variable HR ULSAM (95% CI) p-value HR PIVUS (95% CI) p-value 
Gender, female   N/A  0.73 (0.49, 1.09) 0.121 
Current smoking 1.02 (0.64- 1.61) 0.942 0.83 (0.46- 1.51) 0.545 
BMI  1.09 (0.90- 1.32) 0.354 1.11 (0.92- 1.32) 0.277 
Systolic blood pressure  1.09 (0.90- 1.31) 0.389 1.03 (0.86- 1.23) 0.767 
Antihypertensive treatment 2.32 (1.55- 3.46) <0.001 1.52 (1.05- 2.21) 0.028 
Total cholesterol  0.86 (0.70- 1.04) 0.122 0.87 (0.71- 1.06) 0.168 
HDL cholesterol  1.04 (0.85- 1.27) 0.692 0.89 (0.71- 1.10) 0.286 
Lipid-lowering treatment 0.65 (0.33- 1.31) 0.228 0.96 (0.60- 1.52) 0.847 
Type 2 Diabetes 0.84 (0.44- 1.59) 0.588 0.80 (0.47- 1.35) 0.406 
Heart failure 0.84 (0.12- 6.19) 0.867 N/A  
C index 0.64 (0.59- 0.69)  0.61 (0.56- 0.66)  
Grønnesby Borgan test 0.276  0.578  
Table 4 Cox proportional hazard ratio for incident atrial fibrillation after a median of 
10 years in both cohorts with regards to a model including cardiovascular risk 
factors (gender, age, current smoking, BMI, systolic blood pressure, antihypertensive 
treatment, total cholesterol, HDL cholesterol, lipid-lowering treatment, type 2 
diabetes, and heart failure (only ULSAM)). For continuous variables HR show impact 
of 1 SD increase. HR= Hazard ratio CI= Confidence interval BMI=Body Mass Index.  
In unadjusted analysis all biomarkers were significantly associated with 
incident AF, but the association was strongest for NT-proBNP with a HR of 
2.10 (1.75-2.53) per 1 SD increase in the ULSAM cohort, and 1.63 (1.41-
1.88) in the PIVUS cohort, p < 0.001. Only NT-proBNP remained 
significantly (p < 0.001) associated with incident AF in both cohorts, HR 
2.05 (1.62–2.59) and 1.56 (1.30–1.86) in ULSAM respectively PIVUS, after 
adjustment for both cardiovascular risk factors and biomarkers, Figure 13.  
 
 
 
 
 
 
 
 
 
 
 
Figure 13 Atrial fibrillation incidence in the ULSAM and PIVUS cohort during a 
median follow-up of 10-13 years. Hazard ratios and 95 % confidence intervals (per 1 
SD increase) are shown unadjusted, and adjusted for other biomarkers, and 
cardiovascular risk factors (gender, age, current smoking, body mass index, systolic 
blood pressure, antihypertensive treatment, total cholesterol, HDL cholesterol, lipid-
ULSAM PIVUS 
Adjusted  
for cardiovascular  
risk factors and 
biomarkers 
Unadjusted 
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lowering treatment, heart failure (only ULSAM) and type 2 diabetes. Reprinted 
courtesy of Elsevier. 
C-statistics for incident AF using cardiovascular risk factors was 0.64 (95% 
CI (0.59–0.69)) in ULSAM and 0.62 (95% CI (0.57–0.66)) in PIVUS, which 
increased significantly, p < 0.001, to 0.69 (0.64–0.74) in ULSAM and 0.68 
(0.64–0.72) in PIVUS with the addition of NT-proBNP.  
Using the CHARGE-AF risk score the C-statistic of 0.62 (0.57–0.66) and 
0.60 (0.55–0.65) improved significantly, p < 0.001, to 0.68 (0.63–0.73) and 
0.66 (0.61, 0.70) using NT-proBNP (ULSAM and PIVUS respectively), with 
significant changes also in NRI and IDI. Stratifying for years after follow-up 
this effect was seen to be more pronounced in years 0-2 where C-statistics 
increased from 0.61 (0.52–0.70) to 0.75 (0.64–0.86) with the addition of NT-
proBNP in the ULSAM cohort and 0.60 (0.47–0.72) to 0.78 (0.68–0.89) in the 
PIVUS cohort. 
5.3 STUDY III 
NT-proBNP was analysed in 886 individuals from the Strokestop-study 
(study I). Average CHA2DS2-VASc score did not differ between participants 
who had NT-proBNP analysed compared to participants who did not have 
NT-proBNP analysed.  
The clinical characteristics of the cohort who had NT-proBNP analysed is 
depicted in table 5. 
 Newly detected AF 
n=96) 
No AF  
(n=742) 
p  
Median NT-proBNP, ng/L 330 171 <0.001 
IQR 510 (124;634) 188 (95;283)  
Heart Failure, n (%) 1 (1.1%) 19 (2.6%) 0.718 
Hypertension, n (%) 53 (55.2%) 354 (48.1%) 0.13 
Diabetes Mellitus, n (%) 14 (14.6%) 85 (11.5%) 0.38 
Prior Stroke/TIA, n (%) 10 (10.4%) 73 (10.0%) 0.85 
Vascular disease, n (%) 14 (14.6%) 73 (10.0%) 0.16 
Female gender, n (%) 40 (41.7%) 327 (44.2%) 0.56 
CHA2DS2-VASc, mean (95 % CI) 3.46 (3.24-3.68) 3.35 (3.27-3.43) 0.30 
CHA2DS2-VASc, median  3 (IQR 3;4) 3 (IQR 3;4)  
Height, cm (n=478) 173.3 (CI 171.5-175.1) 171.6 (CI 170.7-172.5) 0.099 
Weight, kg 83.3 (78.8-87.9) 75.7 (74.4-77.0) 0.002 
BMI 27.8 (26.2-29.5) 25.7 (25.3-26.1) 0.014 
Table 5 Baseline characteristics of the participants in Strokestop study who had NT-
proBNP assessed. BMI= Body Mass Index IQR=Interquartile range 
Participants with screen-detected AF, n=96, had significantly higher NT-
proBNP, compared to participants where AF was not detected, n=742.  
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Subject who were in AF at the first visit, n=18, were more likely to have non-
paroxysmal AF, and had significantly higher, p < 0.001, NT-proBNP levels, 
median 847 (IQR 504; 1220), compared to individuals with paroxysmal AF, 
n=78, 227 ng/L (IQR 93;452). Individuals with paroxysmal AF, n=78, had 
significantly higher NT-proBNP levels compared to subjects where no AF 
could be detected (median 227 ng/L (IQR 93;452) vs 171 (IQR 95-283), 
Figure 14. 
 
Figure 14 Box-plot of median levels of NT-proBNP compared to type of atrial 
fibrillation.  
Unadjusted odds ratios for detection of new AF was calculated using binary 
logistic regression, and showed significant association for NT-proBNP, but 
was not significant for parameters included in the CHA2DS2-VASc score. NT-
proBNP remained significantly associated with AF after multivariable 
adjustments, Table 6.  
Variable Unadjusted OR (95% CI) p-value Adjusted OR (95 % CI) p-value 
Heart Failure (Yes) 0.40 (0.05- 3) 0.376 0.19 (0.02- 1.63) 0.130 
Hypertension (Yes) 1.39 (0.91- 2.13) 0.134 1.38 (0.88- 2.18) 0.150 
Diabetes Mellitus (Yes) 1.31 (0.71- 2.42) 0.381 1.05 (0.54- 2.04) 0.897 
Prior stroke/TIA (Yes) 0.93 (0.45- 1.93) 0.851 0.68 (0.30- 1.53) 0.355 
Vascular disease (Yes) 1.54 (0.83- 2.86) 0.167 1.21 (0.60- 2.44) 0.596 
Gender (female) 0.88 (0.57- 1.36) 0.562 0.88 (0.55- 1.39) 0.571 
NT-proBNP, ng/L 1.001 (1.001- 1.001) <0.001 1.001 (1.001- 1.002) <0.001 
Table 6 – Univariate and multivariable analysis for newly detected AF. OR=odds 
ratio TIA=transient ischaemic attack  
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Height and weight were added in a second step in the analysis showing that 
for every 1 cm increase in height OR was 1.05 (1.0-1.1, p=0.04), and for 
weight OR was 1.03 (1.01-1.05, p<0.001) per 1 kg increase. C-statistics for 
NT-proBNP was 0.64 (CI 0.57-0.71), which improved to 0.71 (CI 0.64-0.77) 
with the addition of weight. 
Using frequency matching the participants were randomized into two 
groups, and in the first group a cut-off level for NT-proBNP was determined 
using ROC-curves. A cut-off of 125 ng/L was considered optimal based on 
its sensitivity of 75%. This result was validated in the second group showing 
a sensitivity of 75.5% and a negative predictive value of 92%. Using this cut-
off 33% fewer would have needed to go through screening. The cost 
reduction was estimated to 800 SEK (=94 USD) per patient not needing to 
pass prolonged screening, which is a cost reduction of 35 %.   
5.4 STUDY IV 
There were 41 patients included, subsequently one patient was excluded 
due to a brain tumor initially misdiagnosed as a stroke. ILR implantation 
was achieved at a mean of 6.8 +/- 4.3 days post-event without 
complications, and all participants still had their ILRs at the one-year 
follow-up.  The average age of participants was 76.3 +/- 5.4 years. No 
significant differences in age, gender, NIHSS-score and CHA2DS2-VASc 
score was found between the groups where AF was detected compared to 
the group without detected AF.  
A new diagnosis of AF was made in 14/40 patients, Figure 15, and OAC 
treatment was initiated in all of these. There were significantly (p < 0.001) 
more patients (13/14) detected using ILR compared to both intermittent 
ECG recordings (1 patient detected) and 24-hour Holter monitoring (0 
patients detected). The average time to detect AF was 14.7 +/- 11.6 months, 
and a diagnosis of AF was made within six months of the index event in 
5/40 (12.5%) patients.  
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Figure 15 Kaplan-Meier curve depicting survival free of AF-event in months from start 
of study (=ILR implantation). Dotted line depicts end of recording with intermittent 
ECG recordings at 30 days. 
Unadjusted Cox regression with clinical characteristics included in CHA2DS2-VASc, 
NIHSS dichotomized (≤3 and ≥4), and thrombolysis/thrombectomy was performed, 
Table 7.  
 Unadjusted HR p-level 
Age  1.04 (0.94-1.14) 0.49 
Thrombolysis/thrombectomy  1.39 (0.97-2.00) 0.08 
NIHSS ≥4 3.90 (1.20-12.74) 0.024 
Hypertension 0.65 (0.23-1.89) 0.43 
Diabetes Mellitus 1.02 (0.23-4.58) 0.98 
Prior stroke/TIA 0.70 (0.20-2.53) 0.59 
Vascular disease  0.56 (0.13-2.52) 0.45 
Gender (female) 1.61 (0.55-5.05) 0.37 
Table 7 – Unadjusted hazard ratio for detection of atrial fibrillation using Cox regression with time 
variable time to event or censoring. NIHSS was dichotomized with NIHSS 0-3 as referent variable, 
and NIHSS ≥4 as outcome variable.  NIHSS = National Institutes of Health Stroke Scale 
TIA=Transient Ischemic attack HR=Hazard ratio 
Participants with NIHSS score ≥4 were more likely to be diagnosed with AF, Figure 
16.   
 42 
 
Figure 16 - Cox regression hazard model for AF detection in dichotomized groups 
with NIHSS ≥4 compared to group with NIHSS ≤ 3 
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6 GENERAL DISCUSSION 
6.1 MAJOR FINDINGS 
In the first systematic prolonged screening study for AF, Strokestop, that 
was performed in a population at a high risk for stroke, we showed that 
systematic AF screening is feasible and identifies a significant proportion of 
untreated AF.  
In our second study we used five biomarkers depicting various 
pathophysiological pathways in two cohorts to identify biomarkers that 
might be associated with increased risk of developing AF over time. This 
study confirmed that only NT-proBNP was associated with development of 
AF if other risk factors and biomarkers were adjusted for.  
This biomarker, NT-proBNP, was subsequently used in study III and was 
shown to be increased in participants in whom AF was detected during 
screening for atrial fibrillation. In this study a cut-off for NT-proBNP was 
identified that could help identify a population that was more likely to 
benefit from screening for AF.  
In patients at very high risk of stroke who had already had a prior 
stroke/TIA, we could show that prolonged screening using implantable loop 
recorders detected a large proportion of treatable AF. 
6.2 WHY SCREEN FOR ATRIAL FIBRILLATION? 
Atrial fibrillation, already a common condition, with prevalence in the adult 
Swedish population of approximately 3% 20, is expected to double in the 
coming decades 23 24, which would give rise to an AF epidemic.  
AF doubles mortality and increases the risk of stroke five-fold 3, 29. This risk 
can be reduced significantly using OAC-therapy 31.  
AF is commonly asymptomatic 110, but the risk of stroke is no less 
significant 40 compared to individuals with symptomatic AF, and the risk of 
stroke in incidentally detected AF can be reduced substantially using OAC-
treatment 42. 
Almost a tenth of >94,000 patients with ischemic stroke also presented with 
a new diagnosis of AF in a Swedish register study 93. In addition, inadequate 
treatment 34 of AF is common, especially in high risk individuals, with only 
22% receiving OAC-therapy in the six months preceding the stroke93.  
AF detection is easy, and not harmful for the patient 54 50, 53.  
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Hence, AF fulfils most of the WHO criteria for screening 89. Using population 
screening as in paper I, a large proportion of newly detected AF can be 
identified and OAC treatment initiated. In addition, as shown in study I, 
population screening can be used to identify individuals with inadequately 
treated AF.  
6.3 POPULATION SCREENING - WHO TO SCREEN? 
Prior screening efforts for atrial fibrillation have mainly focused on either 
specific subgroups at high risk of stroke 98, 101, 111 or single time-point 
screening for atrial fibrillation in population screening 45, 49, 51, 53.  
Single time-point screening is more likely to detect individuals with non-
paroxysmal forms of AF. In one global and one European study of AF 
patients paroxysmal AF represented > 25% of the patients in routine clinical 
practice 36, 112.   
The current guidelines for OAC therapy do not take into account AF type 3 
as similar risk of stroke in paroxysmal and persistent AF have been shown 
37, 38. A recent meta-analysis of almost 100,000 patients stratified into 
paroxysmal and non-paroxysmal AF showed that the adjusted risk for 
thromboembolism was almost 40% higher in the non-paroxysmal group 39. 
Although the risk of stroke is higher in the non-paroxysmal group, the risk 
of stroke was still significant in the paroxysmal group, and individuals with 
paroxysmal AF often progress to non-paroxysmal forms 91. The type of AF 
could possibly be of guidance when making treatment decisions in men with 
CHA2DS2-VASc 1 and women with CHA2DS2-VASc 2 where OAC treatment 
is based on an individualized weighing of risks 3. Patients with higher 
CHA2DS2-VASc scores still have significant risk of stroke, and OAC-therapy 
should be initiated regardless of AF type 3.  
In study I we showed that when screening individuals aged 75/76, hence 
with CHA2DS2-VASc scores of 2/3 regardless of other risk factors, prolonged 
monitoring increased AF detection 6-fold, and the majority of patients with 
newly detected AF had paroxysmal AF. In this high-risk group, it could be 
argued that the presence of paroxysmal AF merits OAC therapy. 
Age is of utmost importance when screening for AF; indeed the prevalence of 
AF increases steeply with age 21. There is low yield of AF detection in 
populations that are younger than 65 years of age 49. In one single time-
point screening study 51 performed in influenza clinics in Holland, not a 
single new AF was detected in participants below the age of 60. In addition, 
age is one of the strongest predictors of stroke in patients with AF 95 and is 
  45 
a bellwether in identifying likely beneficiaries of stroke-preventive OAC-
therapy 3.  
In a prior study in Sweden 75/76-year-olds were invited to a step-wise 
screening for AF, where only individuals with one additional risk factor for 
stroke were offered prolonged screening 55. This model showed a high 
detection rate of atrial fibrillation.   
In study I we chose a more simplified approach that is to screen all 
individuals based on a simple age criterion. We chose ages 75/76 as they 
have a high prevalence of AF, are at high risk of stroke should they have 
untreated AF, and have indication for OAC-therapy regardless of other 
clinical risk factors, should the condition be discovered 3. However, there is 
no prior similar prolonged screening made in other age groups, and the 
optimal age for population screening is a matter for future research.  
In study I we are able to show that by using a systematic approach and 
intermittent screening for atrial fibrillation we could increase the detection 
of atrial fibrillation six-fold from 0.5% at the time of the first ECG to 3% 
after intermittent ECG screening. In a simulated health-economic study, the 
screening effort was also shown to be cost-effective 92, with the potential of 
avoiding 8 strokes per 1,000 individuals screened, and with a cost of € 
4,313 per gained quality adjusted life years (QALY).  
These studies formed the basis for a new recommendation in the 2016 ESC 
guidelines for AF 3: 
“Systematic ECG screening may be considered to detect AF in patients aged 
>75 years or those at high stroke risk”. (IIb) 
6.4 HOW TO MAKE SCREENING FOR AF MORE EFFICIENT? 
With an ageing population, health resources will be scarce and it will be a 
priority to simplify, and make screening for AF as efficient as possible. 
Intermittent screening for AF will yield many ECGs: study I alone yielded 
189,715 ECGs to manually interpret. The use of a computerized algorithm 
that could reduce the need for manual interpretation would decrease the 
cost and work load of prolonged screening. Such an algorithm has recently 
been developed, showing that the algorithm can safely identify normal sinus 
rhythm with a negative predictive value of 99.9% and a sensitivity for AF 
detection of 100% on an individual basis 113. 
Of those invited to screening, 54% chose to attend. This attendance is lower 
than other Swedish screening programs 114, 115 116. The reasons for this 
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could be: 1) fewer will attend a research study than a screening program in 
regular health care, 2) the condition AF might still be quite unknown to the 
general public, giving rise to a knowledge gap in that they do not perceive 
the condition as being dangerous. 3) The participants in our study were 
generally older, which could affect participation due to concomitant disease. 
4) The screening effort of a two-week screening procedure could be perceived 
as more cumbersome compared to a single-time point screening program. 5) 
The invitation was only issued in Swedish, and a socio-economic study of 
participants show that participation is lower in the group born outside of 
Sweden 117. In addition, it was shown that geographic distance to screening 
was significant, at least in the Stockholm region where there was a single 
screening centre 117.  
In a prior study, non-participants in a systematic AF screening study had 
more concomitant disease and higher incidence of stroke 118. These 
individuals might be more likely to have AF. Additionally, in breast cancer 
screening programs, individuals not attending were shown to have a higher 
incidence of advanced breast cancer 119. Hence individuals with higher risk 
of the disease and with difficulties travelling are less likely to attend 
screening, which could introduce a selection bias and possibly an 
underestimation of AF prevalence.  
Increased participation could increase the yield of screening-detected AF. 
This might be the reason why significantly more AF was discovered in the 
rural region of Halland where participation was higher compared to the 
Stockholm region in study I.  
If invitations are issued in languages other than Swedish and if geographic 
distances are reduced, participation may increase and detection of AF may 
increase even further. 
One way to identify individuals who would benefit more from screening 
could be the addition of a biomarker. Several cohort studies using 
biomarkers have shown an association with different biomarkers and the 
development of AF (64-67, 73). The majority of these studies have not adjusted 
for the presence of other biomarkers. In one prior study by Rienstra et al., it 
was shown that the addition of ST-2, GDF-15 or hs-TnI did not improve AF 
risk discrimination beyond the use of clinical risk factors and biomarkers 
BNP and CRP 75. In our second study we confirm these findings and are able 
to conclude that when adjusting for other biomarkers, only NT-proBNP 
remained significantly associated with incident AF.  
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Not only is NT-proBNP a marker of incident AF but in a meta-analysis, NT-
proBNP was one of the main predictors for cardio-embolic stroke 71. In the 
novel oral anticoagulant studies ARISTOTLE and RELY encompassing 
participants with anticoagulated treated AF, individuals with high NT-
proBNP levels had an increased risk of stroke 69 70. The biomarkers NT-
proBNP and troponin have been suggested to be used to assess the risk of 
stroke in AF patients in a new risk score (ABC-score) 33.  
The use of biomarkers in screening has been assessed in a smaller study of 
244 individuals screened for AF using 7-days Holter monitoring. NT-proBNP 
showed high predictive ability of AF 72. These findings were confirmed in 
study III where we could show that participants with screening-detected AF 
had a significantly higher NT-proBNP levels compared to participants where 
AF was not detected.  
Hence, it could be argued that individuals with a low NT-proBNP might have 
a low chance of having AF detected, and in addition have a low stroke risk 
and therefore would not benefit from AF screening.  
This has not been tested prospectively, and this approach is now being 
assessed in a new study, Strokestop 2 (NCT02743416), in which the 
biomarker NT-proBNP is used in 75/76-year olds to decide who will get 
prolonged screening for AF.  
6.5 SCREENING FOR AF IN SPECIFIC RISK GROUPS 
6.5.1 Patients with prior stroke/TIA 
The majority of strokes are of ischemic origin (85%). One in five strokes is 
believed to be cardio-embolic 120, 121, with the majority of cardio-embolic 
strokes being caused by AF121. 
In an unselected population of stroke/TIA patients, 30-days intermittent 
ECG monitoring found significantly more AF compared to 24-hour 
monitoring 97.  
The cause of stroke remains unknown in approximately 25% of patients and 
is classified as cryptogenic 120, 122. It has been speculated that some cases of 
cryptogenic stroke could be due to undiagnosed AF and in meta-analysis, 
new AF was detected in 15.9% with cryptogenic stroke using various 
methods for AF detection 102, 103.  
In the EMBRACE-study patients with cryptogenic stroke were randomized 
into conventional screening for AF with 24-hour Holter compared to 30-days 
event recording. Using 30-days monitoring, 16% new AF was detected 123. In 
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the CRYSTAL-AF trial, patients with a cryptogenic stroke aged 40 and above 
were randomized to having an implantable cardiac monitor (ILR) or follow-
up according to standard-of-care 101. Within 6 months 8.9% of the 
participants in the group with ILR had AF detected, whereas significantly 
fewer (1.4%) had AF detected in the control group. By 12 months AF 
detection in the ILR group increased to 12.4% and by 36 months, 30% had 
AF detected. Interestingly in a sub-group analysis of the patients aged above 
65 (n=165) in the study 17% AF was found at 6 months compared to 2.5% 
in the control group. 
In study IV we used three different methods for AF detection in an elderly 
group with prior ischemic TIA or stroke and found no atrial fibrillation with 
24-hour Holter monitoring. Using 30-days intermittent ECG recording only 
detected one (1) case of AF, which was fewer than reported in a larger study 
97. The detection of AF using ILR was higher at 6 months, 12.5%, compared 
with the CRYSTAL-AF study 101, but our patients were of higher age. 
In unadjusted analysis patients with more severe strokes at onset (signified 
by NIHSS ≥4) were almost four times as likely to have AF detected. Patients 
with AF who get a stroke are commonly more severely afflicted30. Hence, 
possibly more AF would be detected in the group with more severe strokes 
represented by higher NIHSS-scores.  
Taking the large proportion of AF detected in patients with cryptogenic 
strokes, there are currently two ongoing studies, RE-SPECT ESUS 
(NCT02239120) and NAVIGATE ESUS (NCT02313909), in which individuals 
with embolic strokes of undetermined source - that is non-lacunar strokes 
without obvious proximal artery stenosis or cardio-embolic sources 122) -are 
randomized to oral anticoagulant therapy or anti-platelets without AF 
detected.  
6.5.2 Other patient groups 
In a stepwise screening study of 75/76-year-olds 55, it was shown that the 
yield of screen-detected AF increased when prolonged screening was applied 
to individuals with an additional stroke risk factor apart from age.  
In an observational study by Marfella et al, 464 patients with type 2 
diabetes below 60 years of age were followed with 48-hour Holter monitoring 
every three months for three years. AF was detected in 11% of participants 
124. In addition, participants with newly detected AF had higher risk of both 
subclinical and clinical stroke.  
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In study I the multivariable analysis showed that individuals with 
congestive heart failure, prior vascular disease and diabetes were more 
likely to have AF detected. As shown in the study by Marfella et al., the yield 
of AF screening could potentially be higher in these individuals, who also 
have higher risk of stroke. In an ongoing study, SILENCE NCT02893215, 
individuals with heart failure or type 2 diabetes will be screened for AF 
using intermittent ECG recordings during two weeks.  
Women with low BMI were less likely to have new AF detected in study I. 
However, women with AF have higher risk of ischemic stroke 3. Hence, even 
if detection rate of AF is lower, it could still be cost-efficient to screen 
women.  
6.6 HOW TO SCREEN FOR AF? 
Newer technology has the potential to facilitate AF-screening, Table 2. 
Simple hand-held devices have been shown to be accurate and easy to use 
in single time-point AF-screening 50, 52-54. These devices have an additional 
benefit when compared to 12-lead ECG in that they are portable, which 
makes prolonged screening possible. In study I we could show that AF 
detection increased 6-fold if ECG screening was prolonged.  
The only method used in a randomized controlled study is screening using 
pulse-palpation followed by a 12-lead ECG versus routine practice for AF 
detection 45 in the SAFE-study. Screening found significantly more AF 
(1.6%) versus routine practice (1.0%).  
In the SAFE study, the participants were randomized to opportunistic or 
systematic screening for AF. In the initial report there was no significant 
difference in the detection of AF in both groups 45. Interestingly, a minority 
(31/75) were detected within the screening program in the opportunistic 
arm, whereas in the systematic arm the opposite was true with a majority 
discovered within the screening program (52/74). The detection of AF within 
the systematic screening program was 2.2% and for the opportunistic arm, 
detection was 0.9%, which was very similar to the routine practise 125. In 
the opportunistic arm, 46% had both pulse-palpation and an ECG, whereas 
uptake in the systematic screening arm was slightly higher at 53%. In 
conclusion it would seem that opportunistic screening in this study had a 
lower uptake than systematic screening and that detection rate within the 
screening program was lower in opportunistic screening.  
The reported advantage of opportunistic screening is that it is more cost-
efficient 46 as participants seek health care for other reasons, reducing the 
need for invitations. On the other hand, only individuals already seeking 
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health care will get the benefit of the screening program, whereas in 
systematic screening all of those invited will get the same information and 
opportunity to participate. A cost-efficacy analysis of study I has shown that 
systematic screening is cost-efficient 92. 
One hypothesis is that the setting of the screening program would be of 
importance. For instance, patients very familiar with their general 
practitioner’s (GP’s) office might be more prone to partake in a screening 
program. However, comparing the uptake of systematic screening arm in the 
SAFE study (53%) which was performed at the GP’s, with the community 
setting of a screening clinic in our study I (53.8%), there was no difference 
in uptake, although the fact that our patients were older, can affect 
participation due to frailty. Similar results have been shown in a meta-
analysis of AF detection where no difference was seen among the elderly 
whether AF screening was performed in the community screening or 
GP/outpatient clinic 49.  
The SAFE-study did not report on the initiation of OAC-therapy after 
detection of AF. The pathway to treatment for patients with newly 
diagnosed, or previously known, but untreated atrial fibrillation is of utmost 
importance, as there will be no gain in screening for AF unless appropriate 
stroke preventive medication is initiated. In study I dedicated cardiologists 
were the main port of referral, likely being the reason for the high initiation 
rate of OAC-therapy.  
It is likely that the most appropriate setting for AF screening, and the follow-
up path-way, will be country specific.   
6.7 A SOCIETAL PERSPECTIVE ON SCREENING FOR AF 
The reported AF prevalence is around 1%-2% in the US, Europe and Japan, 
whereas the reported prevalence in the rest of the world is lower at 0.5%-1%  
63. The prevalence is probably underestimated both due to lack of data 
acquisition and to the disease’s inherent qualities with lack of symptoms 
and intermittency.  
Men get AF at an earlier age than women: in populations below the age of 
80, AF prevalence is more common in men 63. It also seems that the 
prevalence of AF is higher among white races compared to non-whites 25.  
The prevalence of rheumatic heart disease was estimated in 2010 to be >30 
million 126, remaining a major cause of heart failure and stroke in the world. 
Although primary prevention of the disease would be preferable, OAC-
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therapy could reduce the risk of AF associated stroke in those already 
afflicted. Hence screening for AF in this population might be useful. 
Swedish citizens have a high level of government sponsored health care, and 
it is likely that the majority of patients with permanent arrhythmia already 
have been detected, giving a low detection rate of AF on first ECG in study I. 
A screening program using single time-point ECGs could possibly be more 
efficient in parts of the world where health-care access is lower. In addition 
with new screening methods, ECGs are easy to obtain and with novel oral 
anticoagulants, treatment is easier to administer. However, if screening for 
AF is performed, a pathway for continuity of treatment should be considered 
beforehand.  
In Sweden systematic screening is recommended by the Swedish National 
Board of health and welfare for several diseases, as shown for the adult 
population in table 8 127. 
 
Disease Method Repeated Population  Cost per QALY 
(SEK)/ Euro 
Breast cancer Mammography 
(repeated) 
18-24 months Women aged 40-74 (100,000-500,000) 
€10,389 -51,943 
Abdominal aortic 
aneurysm 
Abdominal ultrasound Once Men aged 65 (70,000)  
€7,272 
Rectal- and colon 
cancer 
Stool sample  
(repeated) 
24 months 60-74  <100,000 
€10,387 
Cervical cancer Smear test & HPV 
cytology 
3-7 years Women aged 23-64  N/A 
Table 8 Screening programs recommended in the Swedish adult population 
The cost-efficiency analysis for study I using intermittent ECG registrations 
for systematic AF screening was €4,313 (SEK 41,516) per QALY, which is by 
the most cost-efficient of screening programs in Sweden. 
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6.8 LIMITATIONS 
The question of whether screen-detected AF causes as much 
thromboembolism as clinically detected AF is of high importance. Studies of 
asymptomatic 40 and incidentally detected AF 42 indicate that this is the 
case. No study has yet shown that systematic AF screening and initiation of 
OAC treatment will reduce the societal stroke burden.  
In study I the participants were randomized to systematic screening or a 
control group, but the prevalence of AF detected in the control group has 
not yet been assessed, hence whether or not systematic intermittent 
screening detects more AF than regular practise has yet to be confirmed. 
That a particular group chose not to attend screening can give rise to a 
selection bias. In study I, hypothetically, more healthy people attend 
screening than non-healthy people. Those who attend screening are 
therefore less likely to get a diagnosis of AF, and hence prevalence in the 
population might be underestimated. Screening might also cause an over-
diagnosis of the condition, that is that AF cases discovered by screening 
might be less harmful and not have the same risk of stroke as clinically 
detected cases. 
Other limitations with screening is lead-time bias, that is that the condition 
is diagnosed earlier than it would be without screening. Subsequently, 
survival with the diagnosed condition will be longer, even though it might 
not affect life-span. There is also length-time bias which means that 
screening is more likely to detect AF that is slowly progressing and possibly 
less dangerous, but screening will not detect AF that progresses rapidly. 
Hence it might appear as though cases that are discovered through 
screening fare better; although, this may just be the nature of the slowly 
progressing disease 88.  
In study I & III, we report only prevalence data of AF. Hence over-diagnosis, 
length-time bias, and lead-time bias are not of concern but these elements 
will need to be considered at the follow-up study as they might lead to over 
interpretation of the clinical gain from systematic screening. However, with 
randomization of the groups to screening or control we intend to analyse the 
data on an intention-to-screen basis, instead of an as-screened basis, which 
will reduce bias. 
In study I no blinding of the investigators was possible, and investigators 
could possibly be prone to over-diagnose AF, causing misclassification bias. 
In order to minimize this all ECGs were reviewed by one nurse and one 
investigating physician. In order to reduce misclassification bias 
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investigators in study III were blinded to the result of the NT-proBNP until 
the ECG interpretation was done.  
In study I & III we used mainly twice-daily, intermittent, 30-second ECG 
recordings to detect AF. As the recordings are intermittent, it is not possible 
to assess the burden of AF. One can assume that an individual in whom AF 
is detected when monitoring is used during such a short span of time is one 
who is likely to have a substantial AF burden. However, many individuals 
with paroxysmal episodes outside of detection times will be missed. We 
neither studied the yield of AF if screening would have been applied several 
times per day, nor compared the intermittent method with a continuous 
method. It is likely that more AF would have been found using a continuous 
method, but these limitations have to be weighed against the high degree of 
compliance and the ease of use of the method. Atrial flutter is difficult to 
detect using 1-lead ECGs 54. These patients could have been missed.   
In study III using the NT-proBNP cut-off of 125 ng/L means that almost 
25% of individuals with new AF will be missed. NT-proBNP might be 
secreted at a higher level if a recent episode of atrial fibrillation has 
occurred. It could also be normal at the time of screening if the duration of 
time since last episode of AF was longer, causing NT-proBNP to be normal at 
the time of screening. This could lead to an underestimation of the risk of 
AF. Prospective studies are needed to clarify if a cut-off for NT-proBNP will 
aid in systematic AF screening. 
We only measured NT-proBNP. Hence, no other biomarkers could be 
studied, and we could not study renal function. Individuals with renal 
failure are more prone to both increased NT-proBNP levels and AF128, 129. 
This makes renal failure a possible confounder.  
In study III the combination of weight and NT-proBNP showed good 
discriminative abilities for AF detection. However, the use of weight in a 
screening program is cumbersome, and individuals who are overweight 
might feel singled-out for screening. 
In study II the primary endpoint was a register diagnosis of AF. This might 
have led to under diagnosis of AF, as individuals with asymptomatic AF 
might not seek health care. The participants in the ULSAM study were only 
male. Hence, generalizability to women from the ULSAM study is low, 
whereas in PIVUS the genders were equally represented. The population in 
both studies are mainly white and elderly; therefore, hence the results may 
not be generalizable to other populations.   
In study II & III  
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Individuals with heart failure often have high NT-proBNP 61. Furthermore, 
individuals with heart failure are more likely to have atrial fibrillation 3, 
which means heart failure could be a confounder for increased NT-proBNP 
and detection of AF. In sensitivity analyses in both studies, the results 
remained significant even if patients with heart failure were removed.     
In study IV only 40 patients were included, and multivariable analysis was 
not performed due to a lack of power. Only patients who were alive after 
their stroke event and who were not too handicapped by their initial stroke 
were included, which might give rise to a selection bias. However, 20% of 
participants had thrombolysis/thrombectomy, indicating that some 
individuals with severe strokes were included. 
The ILR can only record episodes of AF lasting >2 minutes 130, hence shorter 
episodes of AF could have been missed. The importance of shorter episodes 
of AF after a stroke is not known131. 
In our study many first-time episodes of AF were detected a long time after 
the stroke/TIA-event, and the causality between the AF episode and the 
stroke/TIA is difficult to establish. In pacemaker studies the temporal 
relationship between AHREs and stroke have been under debate 132.   
However, individuals with AF who are of high age and who have had a 
stroke/TIA have a very high risk of getting a new stroke, and OAC-therapy 
is warranted regardless 3. 
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7 CONCLUSIONS 
 
Systematic screening using intermittent ECG screening for 14 days in 
individuals aged 75/76 yields a significant amount of newly detected atrial 
fibrillation, and the resulting initiation of stroke-preventive therapy is high. 
Individuals with known atrial fibrillation and inadequate stroke-prophylactic 
therapy were identified during systematic screening, and oral anticoagulant 
therapy was initiated in a majority of those individuals without 
contraindications. 
A biomarker commonly produced by atrial stretch, NT-proBNP, was shown 
in two cohort studies to be the only biomarker out of five that was 
significantly associated with incident AF after adjustment for other 
biomarkers and clinical risk factors. The addition of NT-proBNP significantly 
improved the CHARGE-AF risk score for atrial fibrillation. 
Individuals with screening-detected atrial fibrillation had higher levels of 
NT-proBNP regardless of type of AF detected. A cut-off of NT-proBNP of 125 
ng/L showed a high negative predictive value for screening-detected AF. 
In elderly patients with an ischemic stroke/TIA, parallel investigation of 
three methods for AF detection showed that long-term monitoring using an 
implantable cardiac monitor revealed a large proportion of atrial fibrillation 
and was significantly better at AF detection compared to the two other 
methods. 
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8 CLINICAL IMPLICATIONS 
 
Systematic ECG screening may be considered to detect AF in patients aged 
>75 years according to the 2016 ESC guidelines for atrial fibrillation.  
A high proportion of individuals with screen-detected AF were initiated on 
oral anticoagulant therapy, indicating that a dedicated team of physicians is 
key in empowering patients with regards to decisions about anticoagulants. 
Biomarkers have been shown to be associated with incident atrial 
fibrillation, and their role in clinical decisions with regards to AF detection, 
stroke preventive therapy, and bleeding risk is expected to increase. 
In patients with screen-detected AF, the biomarker NT-proBNP was 
significantly higher than in patients where AF was not detected. A NT-
proBNP cut-off of 125 ng/L was proposed for use in systematic AF 
screening. 
In elderly patients with a prior ischemic stroke or transient ischemic attack, 
a large proportion of AF was detected using implantable cardiac monitors. 
Patients whose initial clinical presentation was more severe had more AF 
detected. Prolonged monitoring should be considered in elderly patients with 
prior stroke/TIA. 
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9 FUTURE PERSPECTIVES  
 
The risk of stroke in patients with atrial fibrillation is individual, and 
screening efforts for atrial fibrillation should be tailored to match this. In 
individuals with a high risk of ischemic stroke in case of untreated AF the 
screening efforts should be extensive, whereas in young individuals without 
risk factors the indication for screening is low.  
Screening for atrial fibrillation should be guided towards those at most risk 
of having the condition and only at those who would benefit from detection, 
and indeed if there is no indication for OAC-treatment screening for AF 
should not be performed. 
In our first study we show that a systematic screening program in 75/76-
year-olds is not only feasible, but that it identifies a large proportion of 
newly detected AF as well. The planned 5-year follow-up will hopefully be 
able to address the important question of whether or not systematic, 
intermittent AF screening will have an impact on the societal stroke burden. 
In addition, the question regarding of whether or not systematic AF 
screening is more efficient at detecting AF than routine practise can be 
addressed. 
Several questions remain with regards to optimal systematic screening 
program for AF: What is the ideal age for systematic screening? Should 
screening be done at an earlier age in particular risk group? Should AF 
screening be repeated and if so, at what interval? When screening for AF 
should other diseases also be screened for? 
What is the ideal device for systematic screening? Given that intermittent 
ECG screening detects significantly more AF than single-time point 
screening, how would continuous monitoring do? For how long should we 
screen? Could biomarkers be used to guide screening-efforts? Is there a 
more specific biomarker for AF that is yet to be found?  
How should we screen for AF in stroke patients? Should individuals with 
embolic stroke of undetermined source be started on oral anticoagulants? 
Taking this reasoning further, should a randomized trial for patients with 
very high CHA2DS2-VASc scores and no known AF be considered, with one 
arm treated with oral anticoagulants? 
What role do shorter episodes of AF, that is bursts of supraventricular 
ectopics, have? Should these patients be screened for AF annually? Should 
OAC-therapy be initiated? What is the risk of stroke in these patients?  
 58 
How could we reach out to all groups in society and make systematic 
screening for AF more equal?  
More studies are warranted in order to answer all of these important 
questions. 
Creating AF-clinics that have the mission to find, treat, and follow patients 
could be proposed. These clinics would have a socio-cultural approach to 
finding AF, in that they would be culturally grounded in the communities 
they serve; making screening possible regardless of socio-economic 
differences and language barriers. There is no point in systematic AF 
screening unless OAC-therapy is initiated in individuals where the risk of 
stroke outweighs the risk of bleeding. However, for stroke risk to be reduced 
continued compliance to OAC-therapy would have to be ensured. AF 
patients have diverse symptoms and over time, as the disease progresses, 
these may change. The AF clinics would ideally deliver state-of-the art care 
and follow and empower patients with regards to their own disease and 
treatment.   
The role of AF burden, and indeed type of AF, is still unknown with regards 
to stroke risk. Prolonged monitoring using event-recorders could possibly be 
of use to try to assess AF burden, AF type, and risk of stroke. In any case, 
the temporality between pacemaker detected atrial high rate episodes and 
stroke is not clear. Why does only a fraction of patients with AF have a 
stroke? What atrial pathology predisposes to thrombogenicity, and could AF 
be a marker of another underlying condition? Could this be elucidated using 
a combination of imaging, and biomarkers in AF patients? 
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10  SVENSK SAMMANFATTNING 
 
Över 30 miljoner människor i världen lever idag med förmaksflimmer (FF), 
vilket har klassats som den vanligaste hjärtrytmrubbningen av klinisk 
signifikans. Förmaksflimmer kan vara svårt att diagnosticera, då ca en 
fjärdedel har förmaksflimmer som är intermittent, och en tredjedel har 
förmaksflimmer som är asymtomatiskt. Den verkliga förekomsten av 
förmaksflimmer är därför sannolikt högre. Förmaksflimmer diagnosticeras 
med EKG, vilket är en enkel, icke-invasiv undersökning, där hjärtrytmen 
monitoreras under en varierande tidslängd. 
Förmaksflimmer är en vanlig orsak till stroke oavsett om patienterna har 
symptom av sitt förmaksflimmer eller inte. Det strokeinsjuknande som 
drabbar individer med förmaksflimmer är mer allvarligt, och leder dubbelt 
så ofta till döden än strokeinsjuknande hos individer utan förmaksflimmer.   
Blodförtunnande behandling med antikoagulantia bör ges som 
strokeförebyggande behandling hos en majoritet av patienter med 
förmaksflimmer, och förebygger strokeinsjuknande med ca två tredjedelar.  
Systematisk screening rekommenderas för andra sjukdomar vilka, liksom 
förmaksflimmer, medför en allvarlig hälsorisk om de är obehandlade, under 
förutsättning att det finns ett test som är acceptabelt.  
Biomarkörer, vilka är ämnen som mäts i blodet, kan användas för att bättre 
förstå en sjukdomsmekanism, och ibland användas för att diagnosticera, 
och riskvärdera olika sjukdomstillstånd. För förmaksflimmer finns idag 
ingen specifik biomarkör.  
Patienter vilka tidigare haft en ischemisk stroke eller transitorisk ischemisk 
attack (TIA), har en förekomst av förmaksflimmer som är mycket hög, och 
de har mycket stor nytta av antikoagulantiabehandling. I tidigare studier 
har det visat sig att om man monitorerar hjärtrytmen efter en stroke/TIA 
hittar man fler patienter med asymptomatiskt FF, vilka har stor nytta av 
antikoagulantia behandling. Den optimala metoden för monitorering av 
hjärtrytmen efter en stroke/TIA är okänd.  
Den här avhandlingens första delstudie syftar till att studera hur mycket 
förmaksflimmer som upptäcks om en äldre befolkningsgrupp systematiskt 
screenas för förmaksflimmer och vilken andel av befolkningsgruppen som 
skulle ha nytta av strokeförebyggande antikoagulantiabehandling. I den 
andra delstudien avses fem biomarkörer, och deras association till 
förmaksflimmer studeras. I den tredje delstudien studeras den biomarkör 
som i studie II visade mest samband med förmaksflimmer, och mäts i blodet 
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hos deltagare i screeningstudie I. I delstudie IV jämförs tre olika metoder för 
att hitta förmaksflimmer hos äldre patienter med genomgången stroke/TIA. 
METOD OCH RESULTAT 
I studie ett valdes hälften av alla invånare, n=28 768, födda 1936/37 i två 
svenska regioner slumpmässigt ut till att bjudas in till screening för 
förmaksflimmer. Av de 13 331 individer som inbjöds till screening deltog 
7 137 (54 %). Med hjälp av tum-EKG screening två gånger dagligen under 
fjorton dagar upptäcktes nytt FF hos 218 individer (3.0 %, 95 % konfidens 
intervall (CI) 2.7–3.5). Dessutom upptäcktes att 149 patienter med känt 
förmaksflimmer inte hade antikoagulantia behandling. Totalt av de som 
deltog i screeningen hade 5.1% (95 % CI 4.6–5.7) FF som ej var 
antikoagulantia behandlat. Hos deltagare med nyupptäckt FF insattes 93 % 
på antikoagulantiabehandling, och totalt i hela gruppen startades 3.7 % (95 
% CI 3.3–4.2) på strokeförebyggande behandling. 
I studie II togs fem olika biomarkörer hos 70/71-åriga deltagare i två stora 
kohorter i Uppsala, Uppsala Longitudinal Study of Adult Men (ULSAM), 
n=1 221 och Prospective Investigation of the Vasculature in Uppsala Seniors 
(PIVUS), n=1 066. Vid studieinklusion undersöktes deltagarnas 
kardiovaskulära risker. Deltagare med känt förmaksflimmer, och deltagare 
där plasmaprover ej kvarstod för biomarköranalys uteslöts, och totalt följdes 
883 deltagare i ULSAM studien i median 12.6 år, och 978 deltagare i PIVUS 
studien i median 10 år, med avseende på om de utvecklade FF. De fem 
biomarkörer som analyserades i deltagarna representerade fem olika 
sjukdomsmekanismer, och bestod av i) N-terminal pro-B-type Natriuretic 
Peptide (NT-proBNP), vilket är en markör för uttänjning av myocyterna i 
förmaket, ii) hög-känsligt (hs) Troponin (Tn), vilket är en markör för 
hjärtmuskelskada, iii) Growth differentiation factor -15 (GDF-15), markör 
för oxidativ stress, iv) njurbiomarkören cystatin C och v) hs CRP som 
inflammatorisk markör.  
I ULSAM studien utvecklade 113 (12.8%) FF, och motsvarande i PIVUS var 
148 (15.1%). Ojusterade Cox regressions analyser visade att alla 
biomarkörer var signifikant associerade med utvecklingen av 
förmaksflimmer, men efter att analysen justerats för kardiovaskulära 
riskfaktorer, och övriga biomarkörer kvarstod enbart NT-proBNP som 
signifikant med en risk ökning per 1 standard avvikelse på 2.05 (1.62–2.59) 
i ULSAM och 1.56 (1.30–1.86) i PIVUS. NT-proBNP förbättrade även 
signifikant riskprediktionen av ett riskskattningsverktyg för förmaksflimmer 
(CHARGE-AF). 
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I studie III mättes NT-proBNP med patientnära analys hos de sista 815 
deltagarna i studie I, och vid uppföljningen hos kardiolog hos 71 deltagare 
med nyupptäckt förmaksflimmer. De 96 deltagarna i studie III med 
nyupptäckt förmaksflimmer hade signifikant, p < 0.001, mycket högre 
nivåer av NT-proBNP, median 330 ng/L (kvartilavstånd (IQR) 510), jämfört 
med deltagare där FF inte hittades, n=742, median NT-proBNP 171 
ng/L(IQR 188). Efter multivariabel logistisk regressionsanalys kvarstod NT-
proBNP som signifikant, p < 0,001, associerat med förmaksflimmer även 
efter justering för övriga kliniska riskfaktorer. Om man vid 
screeningundersökning använder sig av en cut-off på125 ng/L hade man en 
sensitivitet för FF detektion på 75 %.   
I studie IV inkluderades 41 åldrade patienter (medelålder 76.3 +/- 5.4) med 
nyligen genomgången ischemisk stroke/TIA, till att samtidigt genomgå 24 
timmars Holter monitorering, 30 dagars intermittent registrering, och få en 
implanterbar hjärtmonitor (ILR). Inklusion i studien skedde i median 6.8 +/- 
4.3 dagar efter index händelsen. En patient exkluderades sedermera på 
grund av en feldiagnosticerad hjärntumör. Totalt hittades FF hos 14/40 
patienter, samtliga hittades med ILR, medan 30 dagars intermittent 
monitorering hittade en patient med förmaksflimmer. Samtliga patienter 
med nyupptäckt förmaksflimmer kunde startas på antikoagulantia 
behandling.  
SLUTSATSER 
I ett systematiskt screeningprogram för förmaksflimmer hos 75/76 åringar 
hittades en stor andel obehandlade förmaksflimmer, och majoriteten av 
dessa kunde behandlas med stroke-förebyggande behandling. 
I studie II visade sig biomarkören NT-proBNP i två kohortstudier vara 
associerad med utvecklingen av förmaksflimmer, oberoende av kliniska 
riskfaktorer och andra biomarkörer, och visade sig förbättra den gängse 
riskprediktionen för utveckling av förmaksflimmer. 
NT-proBNP mättes i deltagare i ett systematiska screeningprogrammet och 
deltagare med nyupptäckt förmaksflimmer hade högre NT-proBNP värden 
än deltagare utan förmaksflimmer.  
I jämförelsen av tre olika metoder för förmaksflimmerdetektion efter 
stroke/TIA visade sig en implanterbar hjärtmonitor hitta signifikant mer 
förmaksflimmer.  
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